ARCHIVES

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 31 No. 9 | September 26, 2008

Download PDF Visit The Full Archive

Related Articles

Biomarker Identified Predicting Graft-Versus-Host Disease Risk

August 30, 2013

PCORI Approves $54.8 Million For Clinical Effectiveness Research

August 1, 2014

Conferees Set NIH Funding At $30 Billion.

November 2, 2007

BRCA1 and BRCA2 Mutations Linked To Higher Survival

January 27, 2012

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

March 12, 1976

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007